- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02153333
Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™
April 2, 2015 updated by: GlaxoSmithKline
Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following the Administration of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus Vaccine (444563)
This study aims to evaluate the serologic response to PCV-1 in the serum samples previously collected during initiation of vaccination series of Human Rotavirus (HRV) vaccine studies (1-2 months post Dose 2 of HRV vaccine or placebo).
Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
Study Overview
Detailed Description
Serum samples collected from 6 clinical trials previously conducted for HRV vaccine (Rotarix™) are used in this study.
Study Type
Observational
Enrollment (Actual)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 2 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Infants aged 6 to 12 weeks from 6 previously completed clinical trials, who received 2 doses of either Rotarix™ or Placebo.
Description
Inclusion Criteria:
Not applicable as no subjects will be actively enrolled in this study, only the sera samples of the subjects who were a part of previously conducted trials will be used for testing. However, the archived serum samples of only those subjects who satisfy the following criteria will be included in this study:
- Subjects who received two doses of HRV vaccine or Placebo and were included in the ATP cohort for immunogenicity in the primary studies listed.
- Subjects for whom their parents or Legally Acceptable Representatives (LARs) had agreed that their child or wards blood samples could be used for further research while giving consent for any of the primary studies listed.
- Subjects who have sufficient residual volume of serum samples at both pre- and post-vaccination time points.
Exclusion Criteria:
- Not Applicable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HRV Group
Subjects who had received 2 doses of HRV vaccine in previous studies.
|
Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study.
Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
|
Placebo Group
Subjects who had received 2 doses of placebo in previous studies.
|
Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study.
Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seropositivity rates for anti-PCV-1 antibodies.
Time Frame: At 1-2 months post dose 2 of HRV vaccine or placebo.
|
At 1-2 months post dose 2 of HRV vaccine or placebo.
|
Seroconversion rates for anti-PCV-1 antibodies.
Time Frame: At 1-2 months post dose 2 of HRV vaccine or placebo.
|
At 1-2 months post dose 2 of HRV vaccine or placebo.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
May 15, 2014
First Submitted That Met QC Criteria
May 29, 2014
First Posted (Estimate)
June 3, 2014
Study Record Updates
Last Update Posted (Estimate)
April 6, 2015
Last Update Submitted That Met QC Criteria
April 2, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114793
- 444563/005 (Rota-005)
- 444563/023 (Rota-023)
- 444563/028 (Rota-028)
- 444563/029 (Rota-029)
- 102247 (Rota-036)
- 106481 (Rota-054)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Rotavirus
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesUnited States, Finland, Germany, Taiwan, Spain, Costa Rica, Korea, Republic of, Japan
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesJapan
-
GlaxoSmithKlineCompletedRotavirus Infection | Rotavirus VaccinesUnited States
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesJapan
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesBelgium
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedInfections, RotavirusUnited States, Taiwan, Canada, Hong Kong, Turkey
Clinical Trials on Serum sample
-
GlaxoSmithKlineCompletedHepatitis A | Cytomegalovirus | Bordetella Pertussis Infection | Viral Hepatitis Vaccines | Varicella-Zoster Virus | Herpes Simplex (1 and 2)Mexico
-
The Cleveland ClinicCompletedLung Cancer | Biomarkers | Fatty AcidsUnited States
-
Ismail BiyikCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingLupus Erythematosus, SystemicItaly
-
ArtialisCompletedUrine Marking | Effects of; SerumBelgium
-
GlaxoSmithKlineCompletedRotavirus Infection | Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
-
Assistance Publique Hopitaux De MarseilleUnknownChronic Hemodialysis Patients | Caregivers of Chronic Hemodialysis PatientsFrance
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedInfertility, Female | Anovulation | Unexplained InfertilityTurkey
-
GlaxoSmithKlineCompleted